Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dolby Laboratories, Inc. (DLB) vs Humana Inc (HUM) Price & Performance

Dolby Laboratories, Inc.Trade
Humana IncTrade

Price performance (Past 24H)

Key statistics

Dolby Laboratories, Inc. vs Humana Inc — how do they compare? Dolby Laboratories, Inc. trades at $60.43 (market cap $5.75B), while Humana Inc trades at $382.6 (market cap $44.77B). The key difference: Humana Inc is far larger — about 7.8× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays the higher dividend (2.35%). Which is the better fit depends on your goals.

DLBHUM
Market Cap
$5.75B$44.77B
Sector
IndustrialsHealth
52-Week High
$75.62$409.42
52-Week Low
$48.51$163.67
Enterprise Value
$5.12B$52.12B
Dividend Yield
2.35%0.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dolby Laboratories, Inc.

DLB trades at $60.90, down 1.93% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company has consistently beaten EPS estimates in recent quarters, including Q2 2026 with $0.69 actual versus $0.67 expected. Revenue has been stable around $1.3B annually, with a strong gross profit margin of 87.61% in 2025. Analyst consensus is a Buy with a price target of $87.50, suggesting significant upside. Recent news highlights growth in Dolby Atmos and automotive licensing.

The outlook for DLB is positive, supported by strong fundamentals and analyst optimism, but near-term execution risks and licensing volatility pose challenges. The stock's current valuation metrics, including a P/E of 26.11, appear reasonable given growth prospects. Key risks include revenue fluctuations and competitive pressures in the audio-video sector.

Humana Inc

Humana (HUM) trades at $385.47, up 0.12% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue growth remains robust, reaching $129.66B in 2025, though net income margins have compressed to 0.88%. Recent news highlights leadership changes and Medicaid contract wins, while analyst consensus leans Hold with a $409.93 price target.

Outlook is mixed: Medicare Advantage margin expansion plans and cost controls offer upside, but regulatory pressures and margin erosion pose risks. The stock presents a cautious opportunity for investors betting on operational turnaround, with technical support near $382.

Returns comparison

Trailing returns across standard periods

About Dolby Laboratories, Inc.

Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.

Read more on DLB

About Humana Inc

Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Read more on HUM